TipRanks
Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
US Market
Want to see BLTE full AI Analyst Report?

Belite Bio, Inc. ADR (BLTE) Stock Forecast & Price Target

73 Followers
See the Price Targets and Ratings of:

BLTE Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Belite
Bio, Inc. ADR
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BLTE Stock 12 Month Forecast

Average Price Target

$236.86
▲(51.16% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Belite Bio, Inc. ADR in the last 3 months. The average price target is $236.86 with a high forecast of $303.00 and a low forecast of $200.00. The average price target represents a 51.16% change from the last price of $156.69.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"72":"$72","130":"$130","188":"$188","246":"$246","304":"$304"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":303,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$303.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":236.85714285714286,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$236.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$200.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[72,130,188,246,304],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,162.98,173.7507692307692,184.52153846153846,195.29230769230767,206.06307692307692,216.83384615384614,227.60461538461539,238.3753846153846,249.14615384615382,259.91692307692307,270.6876923076923,281.4584615384615,292.22923076923075,{"y":303,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,162.98,168.66285714285712,174.34571428571428,180.0285714285714,185.71142857142857,191.3942857142857,197.07714285714286,202.76,208.44285714285715,214.12571428571428,219.80857142857144,225.49142857142857,231.1742857142857,{"y":236.85714285714286,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,162.98,165.8276923076923,168.67538461538462,171.52307692307693,174.3707692307692,177.21846153846153,180.06615384615384,182.91384615384615,185.76153846153846,188.60923076923078,191.4569230769231,194.30461538461537,197.1523076923077,{"y":200,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":73.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.31,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.58,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.25,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.85,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":142.31,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.61,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.7,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.98,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$303.00Average Price Target$236.86Lowest Price Target$200.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on BLTE
H.C. Wainwright
H.C. Wainwright
$245
Buy
56.36%
Upside
Reiterated
10/15/26
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE), Vertex Pharmaceuticals (NASDAQ: VRTX) and Corcept Therapeutics (NASDAQ: CORT)
Mizuho Securities Analyst forecast on BLTE
Mizuho Securities
Mizuho Securities
$220→$234
Buy
49.34%
Upside
Reiterated
09/09/26
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR), Belite Bio, Inc. ADR (NASDAQ: BLTE) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)
Canaccord Genuity Analyst forecast on BLTE
Canaccord Genuity
Canaccord Genuity
$303
Buy
93.38%
Upside
Initiated
09/04/26
Belite Bio initiated with a Buy at CanaccordBelite Bio initiated with a Buy at Canaccord
Bank of America Securities Analyst forecast on BLTE
Bank of America Securities
Bank of America Securities
$200
Buy
27.64%
Upside
Reiterated
09/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on BLTE
Morgan Stanley
Morgan Stanley
$201→$206
Buy
31.47%
Upside
Reiterated
08/17/26
Morgan Stanley Keeps Their Buy Rating on Belite Bio, Inc. ADR (BLTE)
Cantor Fitzgerald Analyst forecast on BLTE
Cantor Fitzgerald
Cantor Fitzgerald
$266→$270
Buy
72.31%
Upside
Reiterated
08/14/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Belite Bio, Inc. ADR (BLTE)
Maxim Group
$200
Buy
27.64%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE) and Daré Bioscience (NASDAQ: DARE)
StoneX
$187→$217
Buy
38.49%
Upside
Reiterated
03/03/26
Belite Bio price target raised to $217 from $187 at BenchmarkBelite Bio price target raised to $217 from $187 at Benchmark
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on BLTE
H.C. Wainwright
H.C. Wainwright
$245
Buy
56.36%
Upside
Reiterated
10/15/26
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE), Vertex Pharmaceuticals (NASDAQ: VRTX) and Corcept Therapeutics (NASDAQ: CORT)
Mizuho Securities Analyst forecast on BLTE
Mizuho Securities
Mizuho Securities
$220→$234
Buy
49.34%
Upside
Reiterated
09/09/26
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR), Belite Bio, Inc. ADR (NASDAQ: BLTE) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)
Canaccord Genuity Analyst forecast on BLTE
Canaccord Genuity
Canaccord Genuity
$303
Buy
93.38%
Upside
Initiated
09/04/26
Belite Bio initiated with a Buy at CanaccordBelite Bio initiated with a Buy at Canaccord
Bank of America Securities Analyst forecast on BLTE
Bank of America Securities
Bank of America Securities
$200
Buy
27.64%
Upside
Reiterated
09/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on BLTE
Morgan Stanley
Morgan Stanley
$201→$206
Buy
31.47%
Upside
Reiterated
08/17/26
Morgan Stanley Keeps Their Buy Rating on Belite Bio, Inc. ADR (BLTE)
Cantor Fitzgerald Analyst forecast on BLTE
Cantor Fitzgerald
Cantor Fitzgerald
$266→$270
Buy
72.31%
Upside
Reiterated
08/14/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Belite Bio, Inc. ADR (BLTE)
Maxim Group
$200
Buy
27.64%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE) and Daré Bioscience (NASDAQ: DARE)
StoneX
$187→$217
Buy
38.49%
Upside
Reiterated
03/03/26
Belite Bio price target raised to $217 from $187 at BenchmarkBelite Bio price target raised to $217 from $187 at Benchmark
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
IMUXImmunic
OMCLOmnicell
LGNDLigand Pharma
KURAKura Oncology
HITIHigh Tide
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Belite Bio, Inc. ADR

3 Months
Success Rate
9/13 ratings generated profit
69%
Average Return
+22.73%
Copying Michael Okunewitch's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +22.73% per trade.
1 Year
Success Rate
16/19 ratings generated profit
84%
Average Return
+91.69%
Copying Bruce Jackson's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +91.69% per trade.
2 Years
Success Rate
17/19 ratings generated profit
89%
Average Return
+139.25%
Copying Bruce Jackson's trades and holding each position for 2 Years would result in 89.47% of your transactions generating a profit, with an average return of +139.25% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BLTE Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
2
2
1
2
3
Buy
9
8
10
13
11
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
10
11
15
14
In the current month, BLTE has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BLTE average Analyst price target in the past 3 months is 236.86.
Each month's total comprises the sum of three months' worth of ratings.

BLTE Financial Forecast

BLTE Earnings Forecast

Next quarter’s earnings estimate for BLTE is -$0.79 with a range of -$1.16 to -$0.52. The previous quarter’s EPS was -$0.70. BLTE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BLTE has Performed in-line its overall industry.
Next quarter’s earnings estimate for BLTE is -$0.79 with a range of -$1.16 to -$0.52. The previous quarter’s EPS was -$0.70. BLTE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BLTE has Performed in-line its overall industry.
No data currently available

BLTE Sales Forecast

Next quarter’s sales forecast for BLTE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BLTE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BLTE has Performed in-line its overall industry.
Next quarter’s sales forecast for BLTE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BLTE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BLTE has Performed in-line its overall industry.

BLTE Stock Forecast FAQ

What is BLTE’s average 12-month price target, according to analysts?
Based on analyst ratings, Belite Bio, Inc. ADR’s 12-month average price target is 236.86.
    What is BLTE’s upside potential, based on the analysts’ average price target?
    Belite Bio, Inc. ADR has 51.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BLTE a Buy, Sell or Hold?
          Belite Bio, Inc. ADR has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Belite Bio, Inc. ADR’s price target?
            The average price target for Belite Bio, Inc. ADR is 236.86. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $303.00 ,the lowest forecast is $200.00. The average price target represents 51.16% Increase from the current price of $156.69.
              What do analysts say about Belite Bio, Inc. ADR?
              Belite Bio, Inc. ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of BLTE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.